Correction to: AI is a viable alternative to high throughput screening: a 318-target study

Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-024-54655-z, published online 02 April 2024 The original version of this Article contained errors. In the original version of this article, Ellie Giles was omitted from the Author list. Additionally, the following Affiliation information has been updated: 1. Affiliation 25 was incorrect. Affiliation 25 ‘Queensland University of Technology, Brisbane, USA.’ now reads, ‘Queensland University of Technology, Brisbane, Australia.’ 2. Marta Giorgis was incorrectly affiliated with the ‘University of Aberdeen, Aberdeen, UK.’ The correct Affiliation is listed below: ‘University of Turin, Turin, Italy.’ 3. Affiliations 52, 125 and 261 were duplicated. As a result, the correct Affiliation for Andrew B. Herr, Benjamin Liou, David A. Hildeman, Joseph J. Maciag, Ying Sun, Durga Krishnamurthy, and Stephen N. Waggoner is: ‘Cincinnati Children’s Hospital Medical Center, Cincinnati, USA.’ Furthermore, an outdated version of Figure 1 was typeset. The original Figure 1 and accompanying legend appear below. (Figure presented.) Pairs of representative compounds extracted from AI patents (right) and corresponding prior patents (left) for clinical-stage programs (CDK7^92,93, A2Ar-antagonist^94,95, MALT1^96,97, QPCTL^98,99, USP1^100,101, and 3CLpro^102,103). The identical atoms between the chemical structures are highlighted in red. Lastly, The Acknowledgements section contained an error. “See Supplementary section S1.” now reads, “See Supplementary section S2.” The original Article has been corrected.